Author Correction: Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis

Affiliations

• ¹ Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA. toni_choueiri@dfci.harvard.edu.
• ² Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN, USA.
• ³ South Texas Accelerated Research Therapeutics (START), San Antonio, TX, USA.
• ⁴ Fox Chase Cancer Center, Philadelphia, PA, USA.
• ⁵ University of Miami, Miami, FL, USA.
• ⁶ Beth Israel Deaconess Medical Center, Boston, MA, USA.
• ⁷ Massachusetts General Hospital, Boston, MA, USA.
• ⁸ University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
• ⁹ Merck & Co., Inc, Kenilworth, NJ, USA.
• ¹⁰ The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ejonasch@mdanderson.org.